ResearchRSS3 days ago
Scientists discovered that blocking a protein pathway called JNK in the body may help treat spinal muscular atrophy (SMA), a disease that weakens muscles. In mice with severe SMA, blocking this pathway reduced how bad the disease got and helped the mice live longer. This new approach could work by itself or combined with medicines that are already approved for SMA.
WHY IT MATTERSIf this JNK pathway blocking approach moves to human trials, it could offer SMA patients a new treatment option, potentially as a combination therapy with existing approved drugs like nusinersen or onasemnogene abeparvovec.
Clinical trialUNITERAREApr 3
Researchers are testing a new treatment approach for elderly patients with a type of blood cancer (MDS or AML) that has come back or stopped responding to previous treatments. The study uses a combination of chemotherapy drugs followed by a stem cell transplant from a donor to try to help patients recover. This trial is now actively looking for patients to participate.
WHY IT MATTERSThis trial offers elderly patients with relapsed or refractory MDS/AML a potentially less toxic conditioning regimen before stem cell transplant — cladribine-bridged LABU may improve tolerability compared to standard high-dose approaches in this vulnerable population.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new way to help young people with rare bone diseases get better. The program combines sailing therapy (being out on the water) with online rehabilitation exercises that patients can do at home. This study builds on earlier successful results and will compare two different treatment approaches to see which works best.
WHY IT MATTERSThis trial offers young patients with rare skeletal disorders access to an innovative rehabilitation model combining in-person sailing therapy with remote maintenance care, potentially improving outcomes beyond traditional therapy alone.
ResearchCLINICALTRIALSMar 26
Researchers are studying how doctors treat a rare muscle weakness disease called generalized myasthenia gravis (gMG) in Russia. They want to understand what treatments work best in real-world practice by following 450 patients over time. This study is not testing a new drug, but rather collecting information about treatments that are already being used.
WHY IT MATTERSIf you have AChR-antibody positive generalized myasthenia gravis in Russia, this study could help doctors understand which current treatment approaches work best for patients like you in your region.
ResearchCLINICALTRIALSMar 26
Researchers completed a study following 137 patients with Chronic Granulomatous Disease (CGD), a rare immune system disorder. The study compared patients who received a bone marrow transplant (a procedure to replace damaged blood-forming cells) to patients who received standard medical care instead. This research helps doctors understand which treatment approach works best for CGD patients.
WHY IT MATTERSThis completed analysis provides real-world evidence comparing bone marrow transplant outcomes to standard care for CGD patients, which can help your doctor recommend the most effective treatment strategy for your specific situation.